Sanofi reported €1,031 million of intangible asset impairments for the second quarter of 2026 and completed a €1,009 million share buyback covering 1.05% of its share count. The most followed narrative points to a fair value of €96.70, implying the stock is 23% undervalued compared with its last close of €74.47. The valuation case rests on steady top-line growth, rising margins, and a lower future earnings multiple, supported by innovative product launches and a strong R&D pipeline that includes multiple Phase III readouts through 2026 and expansion of biologics such as Dupixent and amlitelimab. Key risks include intensifying pricing pressure in vaccines and potential failures of late-stage pipeline assets.
Sanofi SACompletes €1 billion buyback and reports impairment, with valuation case citing undervaluation and growth prospects.